Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





SARS-CoV-2 Neutralizing Antibodies Fade Quickly in Recovering COVID-19 Patients After Symptoms Subside

By HospiMedica International staff writers
Posted on 19 Oct 2020
SARS-CoV-2 antibody levels in the blood of COVID-19 patients decline rapidly during the weeks after their bodies have cleared the virus and symptoms have subsided, according to a new study.

Researchers at the University of Montreal (Montreal, QC, Canada) are attempting to understand how the levels of antibodies change over time in order to optimize the use of blood plasma from recovering patients for treating those with severe COVID symptoms. More...
Their research is also critical for understanding the efficacy of COVID-19 vaccines and finding out whether previously infected people face a risk of re-infection. Previous studies have revealed that antibodies against the SARS-CoV-2 spike protein peak two or three weeks following the onset of symptoms. In an earlier study of more than 100 patients by researchers at the University of Montreal, it was found that plasma’s ability to neutralize the SARS-CoV-2 virus declined significantly between three and six weeks after the onset of symptoms.

In the new longitudinal study, the team analyzed blood samples collected at one-month intervals from 31 individuals who were recovering from COVID-19. The researchers measured the levels of immunoglobulins that act against the coronavirus S protein and tested the ability of the antibodies to neutralize SARS-CoV-2. They found that the levels of Immunoglobulins G, A, and M that target the binding site declined between six and 10 weeks after the onset of symptoms and the ability of the antibodies to neutralize the virus also reduced over the same period.

Small studies have found that convalescent plasma can reduce the severity of illness and reduce hospitalization in COVID-19 patients, but it is yet to demonstrate benefits in randomized trials. Recovering patients cannot donate blood until at least 14 days after symptoms have subsided in order to allow their body to clear the viral particles, although the researchers have concluded that convalescent plasma must be collected during a specific window of time after recovery for deriving any clear benefits.

“We don’t want to transfuse the virus, just transfuse the antibodies,” said Andrés Finzi, Ph.D., at the University of Montreal. “But at the same time, our work shows that the capacity of the plasma to neutralize viral particles is going down during those first weeks.”

Related Links:
University of Montreal


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.